Lapatinib, a tyrosine kinase inhibitor (TKI) targeting HER2 and EGFR, blocks downstream signalling by inhibiting tyrosine phosphorylation, suppressing tumour growth, and inducing apoptosis. Here, ERBB2 is linked to neoplasm.